Transdermal system containing progestin

Phase 3

MYLAN (VTRS)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

May '27

VTRSPhase 3$17.9B

Transdermal system containing progestin Phase 3 Est. Readout

Transdermal system containing progestin• Female Contraception1,630

May 2027~Confirmed

CT.gov

00%

Mar '27

VTRSPhase 3$17.9B

Transdermal system containing progestin Phase 3 Est. Readout

Transdermal system containing progestin• Female Contraception1,500

Mar 2027~ConfirmedSTALE

CT.gov

00%

Competitive Landscape

0 competitors in Female Contraception

View Full Landscape

Drug Information

Target Indication

Female Contraception

Clinical Trial

NCT06672016

Last updated: 12/13/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

VTRS

MYLAN

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

MYL-1601D ProductPhase 3

Diabetes Mellitus, Type 1

venlafaxine ER 75 mg/day (fixed dose)Phase 3

Major Depressive Disorder

LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATIONPhase 3

Glaucoma, Primary Open Angle (POAG)

RevefenacinPhase 3

Chronic Obstructive Pulmonary Disease, COPD

Amlodipine/atorvastatin single pillPhase 3

Hypertension

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts